D05 - Integrate Type 1 Diabetes Breakthroughs into Your Clinical Paradigm: Breakthrough T1D Update

Sunday, August 11, 2024

10:15 AM – 11:00 AM CT

CE/CME Hours: .75

CE/CME Hours: .75
Pharmacology Hours: 0.0
Activity Type: Knowledge
UAN: JA4008258-0000-24-142-L01-P
CHES/MCHES: .75

Over the past 10 years, there have been significant advances in T1D care and management, including CGM, automated insulin delivery, early prediction through screening, and an FDA-approved therapy to delay the onset of Stage 3 type 1 diabetes. Adoption and clinical implementation, however, are variable and contribute to widening disparities. Join this session to learn about recent advancements in type 1 diabetes technology and therapeutics, discover resources to integrate them into your clinical paradigm, and hear an overview of the short and long-term research pipeline.

Primary Presenter(s)

Anastasia Albanese-O'Neill, PhD, APRN, FADCES (she/her/hers)

Associate Vice President
Breakthrough T1D (formerly JDRF)
Gainesville, Florida

Disclosure(s): No financial relationships to disclose

Slides Slide Player

Co-Presenter(s)

Sanjoy Dutta, PhD

Chief Scientific Officer
Breakthrough T1D (formerly JDRF)
New York, New York

Disclosure(s): Sanofi: Consultant / Advisory Board (Ongoing), Consultant / Advisory Board (Ongoing)

Moderator(s)

Natalie J. Bellini, DNP, FNP-BC, BC-ADM, CDCES (she/her/hers)

Assistant Professor of Medicine/Program Director Diabetes Technology
Case Western Reserve University/University Hospitals
Shaker Heights, Ohio

Disclosure(s): Abbott: Speakers' Bureau (Ongoing); ASCENSIA Diabetes Care: Speakers' Bureau (Ongoing); Embecta: Consultant / Advisory Board (Ongoing); MannKind: Speakers' Bureau (Ongoing); Medtronic: Speakers' Bureau (Ongoing); Sanofi: Speakers' Bureau (Ongoing)